Q3 EPS Estimates for FibroBiologics Boosted by HC Wainwright

FibroBiologics Inc. (NASDAQ:FBLG) – HC Wainwright raised their Q3 2026 earnings estimates for FibroBiologics in a research note issued on Tuesday, August 4th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings per share of ($0.63) for the quarter, up from their prior forecast of ($0.94). HC Wainwright has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for FibroBiologics’ current full-year earnings is ($4.01) per share. HC Wainwright also issued estimates for FibroBiologics’ Q4 2026 earnings at ($0.63) EPS, FY2026 earnings at ($3.00) EPS, FY2027 earnings at ($3.25) EPS, FY2028 earnings at ($4.00) EPS, FY2029 earnings at ($4.89) EPS and FY2030 earnings at ($4.23) EPS.

FibroBiologics (NASDAQ:FBLG) last released its earnings results on Friday, July 31st. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.93) by $0.27.

A number of other equities research analysts have also recently weighed in on the company. Deutsche Bank Aktiengesellschaft cut FibroBiologics to an “underperform” rating in a report on Tuesday. Weiss Ratings raised shares of FibroBiologics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, July 24th. Wall Street Zen upgraded shares of FibroBiologics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 13th. Finally, Maxim Group downgraded shares of FibroBiologics from a “buy” rating to a “hold” rating in a report on Monday, May 4th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, FibroBiologics presently has an average rating of “Reduce” and a consensus target price of $73.00.

FibroBiologics Stock Performance

NASDAQ:FBLG opened at $0.87 on Thursday. FibroBiologics has a 1 year low of $0.62 and a 1 year high of $12.80. The stock has a fifty day moving average price of $0.86 and a two-hundred day moving average price of $2.85. The stock has a market capitalization of $5.78 million, a price-to-earnings ratio of -0.17 and a beta of 1.20.

Institutional Investors Weigh In On FibroBiologics

Large investors have recently made changes to their positions in the business. Jane Street Group LLC acquired a new position in shares of FibroBiologics during the fourth quarter worth about $34,000. Renaissance Technologies LLC raised its holdings in shares of FibroBiologics by 287.3% during the 4th quarter. Renaissance Technologies LLC now owns 231,600 shares of the company’s stock valued at $52,000 after buying an additional 171,800 shares during the period. Geode Capital Management LLC raised its holdings in shares of FibroBiologics by 20.7% during the 4th quarter. Geode Capital Management LLC now owns 348,761 shares of the company’s stock valued at $78,000 after buying an additional 59,813 shares during the period. AMG National Trust Bank acquired a new position in FibroBiologics during the 4th quarter worth approximately $31,000. Finally, Landscape Capital Management L.L.C. acquired a new position in FibroBiologics during the 3rd quarter worth approximately $191,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.